TENOFOVIR

This brand name is authorized in Nigeria.

Active ingredients

The drug TENOFOVIR contains one active pharmaceutical ingredient (API):

1
UNII F4YU4LON7I - TENOFOVIR DISOPROXIL
 

Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination.
 
Read more about Tenofovir disoproxil

Packages

This drug has been approved in Nigeria as follows:

Identifier Form Presentation Description Approval
C4-0362 Tablet JYNA TENOFOVIR DISOPROXIL FUMARATE TABLETS 300 MG TAB 300 mg "TENOFOVIR DISOPROXIL FUMARATE TABLETS ARE INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTED ADULTS." 07/05/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
J05AF07 Tenofovir disoproxil J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
Discover more medicines within J05AF07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
NG Registered Drug Product Database C4-0362

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈